MORARI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 609
AS - Asia 93
EU - Europa 92
Totale 794
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 608
CN - Cina 71
IT - Italia 57
VN - Vietnam 16
FI - Finlandia 11
SE - Svezia 9
GB - Regno Unito 7
HK - Hong Kong 4
DE - Germania 3
FR - Francia 2
SG - Singapore 2
CA - Canada 1
NL - Olanda 1
RS - Serbia 1
UA - Ucraina 1
Totale 794
Salva come PNG Salva come JPEG
Città #
Fairfield 114
Woodbridge 82
Chandler 61
Houston 52
Seattle 41
Ashburn 40
Wilmington 38
Beijing 37
Cambridge 33
Ann Arbor 19
Ogden 18
Dong Ket 16
Padova 16
San Diego 15
Venice 11
Milan 10
Medford 9
Princeton 9
Roxbury 7
Des Moines 6
Helsinki 6
Nanjing 6
Hong Kong 4
Boardman 3
Amsterdam 2
Bologna 2
Catania 2
Chester 2
Hebei 2
London 2
Mira 2
Phoenix 2
Ridgewood 2
Shenyang 2
Singapore 2
Belgrade 1
Cagliari 1
Calgary 1
Catford 1
Council Bluffs 1
Fuzhou 1
Guangzhou 1
Hounslow 1
Jinan 1
Kharkiv 1
Langfang 1
Los Angeles 1
Milton Keynes 1
Montebelluna 1
Nanchang 1
Padenghe sul Garda 1
Prescot 1
Rambouillet 1
Sedilo 1
Senftenberg 1
Serra 1
Strasbourg 1
Tianjin 1
Wandsworth 1
Washington 1
Zhengzhou 1
Ürümqi 1
Totale 702
Salva come PNG Salva come JPEG
Nome #
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice 132
Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4 127
Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotic-Induced Weight Gain 107
LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex 101
Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging 83
Role of LRRK2 in the regulation of dopamine receptor trafficking 73
LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation 41
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease 17
Early dysfunction of substantia nigra dopamine neurons in the parkinq311x mouse 15
Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity 11
Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease 9
Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release 7
Nociceptin/orphanin FQ receptor agonists as a novel therapy for preventing levodopa-induced dyskinesia 7
Autophagy and LRRK2 in the Aging Brain 6
6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata 5
PRIN 2010-2011. Ente finanziatore MIUR. titolo "Discinesie indotte da L-DOPA nella malattia di Parkinson: nuovi meccanismi e target molecolari" 4
In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity 4
Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice 4
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease 3
Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates 3
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats 3
Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease 3
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists 3
Safinamide modulates striatal glutamatergic signaling in a rat model of levodopa-induced dyskinesia 3
NR2A and NR2B subunit containing NMDA receptors differentially regulate striatal output pathways 3
G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice 3
NOP receptor ligands and Parkinson’s disease 3
Mitochondrial P2X7 Receptor Localization Modulates Energy Metabolism Enhancing Physical Performance 3
D-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain 3
Alpha-2 adrenoreceptor-mediated decrease in gamma-aminobutyric acid outflow in cortical slices and synaptosomes during morphine tolerance 3
Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia 3
Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology 3
An innovative approach to treat levodopa-induced dyskinesia based on targeting striatal intracellular signalling. Ente finanziatore Fondazione S. Paolo 3
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease 3
The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway 2
Differential involvement of Ras-GRF1 and Ras-GRF2 in L-DOPA-induced dyskinesia 2
Differential regulation of striato-nigral and striato-pallidal pathways by striatal NR2A and NR2B subunit containing receptors 2
PRIN 2008. ente finanziatore MIUR. titolo"Nuovi approcci terapeutici per le discinesie indotte dal trattamento con L-DOPA in un modello sperimentale di Parkinson: ruolo delle subunità del recettore NMDA e della via molecolare Ras-ERK" 2
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats 2
Dopamine D1 and D2 receptor antagonism differentially modulates stimulation of striatal neurotransmitter levels by N-methyl-D-aspartic acid 2
Nanostructured lipid carriers as delivery systems for parkinson’s therapy 2
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior 2
Translation Imaging in Parkinson’s Disease: Focus on Neuroinflammation 2
Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels 2
Effect of (-)nicotine on GABA efflux from guinea pig cerebral cortex slices 2
Effect of acute and subchronic nicotine treatment on cortical efflux of [3H]-D-aspartate and endogenous GABA in freely moving guinea-pigs 2
Nociceptin/orphanin FQ receptor antagonists riverse akinesia in rat parkinsonian models 2
Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs 2
Functional neuroanatomy of the nigrostriatal and striatonigral pathways as studied with dual probe microdialysis in the awake rat-II. Evidence for a N-methyl-D-aspartate receptor regulation of striatonigral GABAergic transmission and motor function 2
Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: Involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity 2
Modeling Parkinson’s disease in LRRK2 rodents 2
Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease 2
Changes of glutamatergic control of striatal acetylcholine release in experimental parkinsonism 2
5-Hydroxytryptamine-mediated effects of nicotine on endogenous GABA efflux from guinea-pig cortical slices 2
Progetto Telethon 2012. (Ente finanziatore Fondazione Telethon) Funzione e disfunzione a livello presinaptico di LRRK2, una proteina chinasi associata alla malattia di Parkinson 2
Development of a new toolbox for mouse PET-CT brain image analysis fully based on CT images and validation in a PD mouse model 2
Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models 2
Nanoparticulate lipidic dispersions for bromocriptine delivery 2
Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia 2
Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato-pallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism 2
Eltoprazine attenuates L-DOPA induced dyskinesia along with GABA and Glutamate release in rat substantia nigra 2
Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease 2
Mitochondrial targeting in LRRK2-associated parkinsonism (PARK8) 2
Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo 2
The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway. Positive interaction with L-DOPA 2
Synthesis and structure activity relationships of delthorphine analogues 2
Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington’s disease 1
Modeling Parkinson's disease in LRRK2 mice: Focus on synaptic dysfunction and the autophagylysosomal pathway 1
Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis 1
The novel delta opioid receptor agonist UFP-512 dually modulates motor activity in hemiparkinsonian rats via control of the nigro-thalamic pathway 1
NR2B subunit blockade does not affect motor symptoms induced by 3-nitropropionic acid 1
In vitro evidence for increased facilitation of striatal acetylcholine release via pre- and postsynaptic NMDA receptors in hemiparkinsonian rats 1
Reciprocal dopamine-glutamate modulation of release in the basal ganglia 1
Striatal glutamate release evoked in vivo by NMDA is dependent upon ongoing neuronal activity in the substantia nigra, endogenous striatal substance P and dopamine 1
Direct and indirect inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitro 1
L-DOPA-induced modulation of GABA and glutamate release in the substantia nigra pars reticulata and globus pallidus in a rat model of dyskinesia 1
Metabotropic glutamate 2 receptors modulate synaptic inputs and calcium signals in striatal cholinergic interneurons 1
Selectivity and Anti-Parkinsons Potential of Thiadiazolidinone RGS4 Inhibitors 1
Neuronal vulnerability following inhibition of mitochondrial complex II: a possibile ionic mechanism for Huntington’s disease 1
Novel therapeutic strategies for treatment of motor abnormalities in Parkinson’s disease: focus on opioid receptors 1
Managing Parkinson's disease: moving ON with NOP 1
Evidence for a striatal NMDA receptor modulation of nigral glutamate release. A dual probe microdialysis study in the awake freely moving rat 1
Nociceptin/orphanin FQ modulates motor behavior and primary motor cortex output through receptors located in substantia nigra reticulata 1
N-methyl-D-aspartic acid differentially regulates extracellular dopamine, GABA, and glutamate levels in the dorsolateral neostriatum of the halothane-anaesthetized rat: an in vivo microdialysis study 1
Somatostatin Release in the Hippocampus in the Kindling Model of Epilepsy: a Microdialysis Study 1
Nociceptin/orphanin FQ receptor antagonists as a novel therapeutic approach to Parkinson’s disease: interaction with levodopa 1
Stimulation of Delta Opioid Receptor and Blockade of Nociceptin/Orphanin FQ Receptor Synergistically Attenuate Parkinsonism 1
Striatal Dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors 1
Endogenous nociceptin/orphanin FQ contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice 1
Functional neuroanatomy of the nigrostriatal and striatonigral pathways as studied with dual probe microdialysis in the awake rat - I. Effects of perfusion with tetrodotoxin and low-calcium medium 1
Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice 1
Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system 1
Lipid nanocarriers containing a Levodopa prodrug with potential antiparkinsonian activity 1
Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism 1
Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands 1
The selective D3 receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats 1
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity 1
Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-Cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4) 1
Physiopathological aspects of NMDA transmission in the basal ganglia. In vitro and in vivo release studies 1
Nocistatin inhibits 5-hydroxytryptamine release in the mouse neocortex via presynaptic G i/o protein linked pathways 1
Totale 899
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.336
article - articoli 5.800
book - libri 16
conference - conferenze 0
curatela - curatele 0
other - altro 184
patent - brevetti 0
selected - selezionate 0
volume - volumi 148
Totale 12.484
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201949 0 0 0 0 0 0 0 0 0 0 28 21
2019/2020154 18 4 4 35 15 11 20 14 18 10 5 0
2020/202193 4 1 4 3 9 3 0 6 14 17 13 19
2021/2022137 10 8 19 10 4 9 5 23 2 6 7 34
2022/202399 22 13 1 19 13 9 0 5 12 1 1 3
2023/2024293 1 6 6 26 14 10 20 134 61 9 6 0
Totale 927